In Brief: Shingrix for Immunocompromised Adults

Date: August 23, 2021 Issue #:  1631Summary:  The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccineShingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression.Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US;Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Shingles Shingrix vaccines varicella zoster virus Source Type: research